arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MADRIGAL PHARMACEUTICALS, INC.

MDGL
$509.67 ▼ -0.71 (-0.14%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

MADRIGAL PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $14.9B
Dividend Yield
Revenue Growth 71.2%
Op. Margin -15.5%
ROIC -5.1%
FCF / Share $0.65
Trailing P/E
Price / Book 22.5x
FCF Yield 0.1%
Debt / Equity 0.65
info Valuation on last close. End-of-day price, Aug 7, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$364.25M
↑ +71.2%
Net Income Profit after all expenses
$-94.39M
↓ -28.9%
Operating Margin Operating profit as % of sales
-15.5%
↑ +48.1% 8th
FCF / Share Free cash flow per share
$0.65
↑ +111.1%
Long-Term Debt Long-term obligations
$340.79M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
17
Financial Health
47
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters